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Previous epidemiological studies have suggested that the risk of breast cancer is increased by 35-
80% among nightshift workers compared to dayshift working peers, with greater risk among those 
who work more frequent shifts throughout a greater number of years. Night shift work has also been 
associated with increased risk of endometrial, prostate and colon cancers. Specifically, it is 
hypothesized that exposure to light at night may increase breast cancer risk by suppressing the 
normal nocturnal production of melatonin, a neurohormone with direct oncostatic properties, and/or 
by increasing production of reproductive hormones since melatonin has also been implicated in 
regulating the pituitary release of gonadotropins and simulating ovarian estrogen production. 
However, these mechanisms have not been comprehensively examined in populations of actual 
nightshift workers, and previous studies have generally relied on a single measure of melatonin at 
one point in time.  
Therefore, in an effort to elucidate the mechanisms underlying the increased risk of breast cancer 
observed among nightshift workers, Dr. Scott Davis, Public Health Sciences Division, and 
colleagues were recently the first to measure urinary 6-sulfatoxymelatonin, the most common 
melatonin metabolite, in addition to luteinizing hormone (LH), follicle-stimulating hormone (FSH) and 
estrogens (estrogen conjugate, E1C) at multiple time points throughout the course of a typical work 
day and subsequent sleep period in 172 nightshift and 151 dayshift-working nurses. Women were 
20-49 years of age and measures were taken during the early to mid-luteal phase of their menstrual 
cycle. 
Urinary 6-sulfatoxymeltonin levels were 62% lower (mean 18.1 vs. 35.3 ng/mg creatinine, p<0.0001), 
while FSH was 62% higher (6.1 vs. 4.6 ng/mg creatinine, p<0.01) and LH was 58% higher (1.8 vs. 
1.2 ng/mg creatinine, p<0.01) during the daytime sleep of nightshift workers relative to the nighttime 
sleep of dayshift workers. Even during a subsequent night off, 6-sulfatoxymeltonin remained 
significantly lower (-42%, p<0.0001) in nightshift compared to dayshift workers. Noctural melatonin 
levels were 69% lower (mean=14.9 ng/mg creatinine, p<0.0001), while FSH and LH were 35% 
(mean 5.8 ng/mg creatinine, p<0.05) and 38% (mean 1.7 ng/mg creatinine, p<0.05) higher, 
respectively, during nighttime work relative to nighttime sleep in dayshift workers. However, no  
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differences in E1C levels were detected between groups, suggesting that the direct oncostatic 
effects of melatonin, rather than elevated reproductive hormones, are the primary mechanism driving 
the increased breast cancer risk among female shift workers. 
Given that work at night is widespread phenomenon, further studies on the impact of various shift 
schedules and routines on physiological and circadian rhythms of workers in real-world 
environments will be required to provide evidence-based recommendations for prevention. To date, 
preventive effects of melatonin supplementation on breast cancer risk have not been clearly 
documented. 
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Impact of the nocturnal circadian melatonin signal (via the mt1 receptor) and its disruption 
by exposure to light at night on molecular/endocrine and dietary/metabolic regulatory 
mechanisms governing breast cancer initiation, growth promotion and progression. 
 
